Edgewise Therapeutics, Inc. (EWTX) is trading at $14.98, down 25.61 percent or $5.15 during Wednesday's trading, after the company announced positive top-line data from its Phase 2 CIRRUS-HCM trial evaluating EDG-7500 in participants with hypertrophic cardiomyopathy.
The stock opened at $14.50 and has traded between $12.18 and $15.69 today, compared to a previous close of $20.13 on the Nasdaq. Volume has surged to 8.58 million shares, significantly above the average of 1.19 million. The stock's 52-week range stands between $12.18 and $38.12.
While the study showed improvements in cardiac function and symptom relief without affecting systolic function, concerns over adverse events, including atrial fibrillation requiring cardioversion, may be weighing on investor sentiment.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.